EXEL vs JAZZ

For growth investors, Exelixis, Inc.

(EXEL) is the stronger pick with 7. 0% revenue growth year-over-year, versus 4. 9% for Jazz Pharmaceuticals plc (JAZZ). Exelixis, Inc. (EXEL) offers the better valuation at 17. 5x trailing P/E (14. 7x forward), making it the more compelling value choice. Analysts rate Exelixis, Inc. (EXEL) a "Buy" — based on 32 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

On forward P/E, Jazz Pharmaceuticals plc is actually cheaper at 9.

5x — notably different from the trailing picture, reflecting expected earnings growth.

Over the past 5 years, Exelixis, Inc.

(EXEL) delivered a total return of +109. 7%, compared to +32. 2% for Jazz Pharmaceuticals plc (JAZZ). Over 10 years, the gap is even starker: EXEL returned +916. 7% versus JAZZ's +58. 3%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), Jazz Pharmaceuticals plc (JAZZ) is the lower-risk stock at 0.

65β versus Exelixis, Inc. 's 0. 80β — meaning EXEL is approximately 23% more volatile than JAZZ relative to the S&P 500. On balance sheet safety, Exelixis, Inc. (EXEL) carries a lower debt/equity ratio of 8% versus 126% for Jazz Pharmaceuticals plc — giving it more financial flexibility in a downturn.

By revenue growth (latest reported year), Exelixis, Inc.

(EXEL) is pulling ahead at 7. 0% versus 4. 9% for Jazz Pharmaceuticals plc (JAZZ). On earnings-per-share growth, the picture is similar: Exelixis, Inc. grew EPS 58. 0% year-over-year, compared to -167. 5% for Jazz Pharmaceuticals plc. Over a 3-year CAGR, EXEL leads at 12. 9% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

Exelixis, Inc.

(EXEL) is the more profitable company, earning 33. 7% net margin versus -8. 3% for Jazz Pharmaceuticals plc — meaning it keeps 33. 7% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: EXEL leads at 37. 6% versus 5. 3% for JAZZ. At the gross margin level — before operating expenses — EXEL leads at 96. 4%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

On forward earnings alone, Jazz Pharmaceuticals plc (JAZZ) trades at 9.

5x forward P/E versus 14. 7x for Exelixis, Inc. — 5. 3x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for JAZZ: -5. 4% to $216. 14.

None of the stocks in this comparison currently pay a material dividend.

All are effectively zero-yield and should be held for capital appreciation rather than income.

For long-horizon retirement investors, Exelixis, Inc.

(EXEL) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0. 80), +916. 7% 10Y return). Both have compounded well over 10 years (EXEL: +916. 7%, JAZZ: +58. 3%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.

In terms of investment character: EXEL is a mid-cap deep-value stock; JAZZ is a mid-cap quality compounder stock. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.